Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called …

Pulmonary fibrosis is a chronic, progressive, incurable interstitial lung disease with high
mortality after diagnosis and remains a global public health problem. Despite advances and …

Rationale: The model most often used to study the pathogenesis of pulmonary fibroses is the
bleomycin (BLM)-induced lung fibrosis model. Several treatments have been efficacious in …

Cryptotanshinone (CTS), a lipophilic compound extracted from root of Salvia miltiorrhiza
(Danshen), has demonstrated multiple pharmacological activities, including anti …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease with limited therapies. Tissue fibrosis
is associated with type 2 immune response, although the causal contribution of immune …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with high mortality and limited effective
therapy. Herein, we reported that fluvoxamine, a selective serotonin reuptake inhibitor …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder
showcasing an interaction between genetic predisposition and environmental risks. This …

Idiopathic pulmonary fibrosis (IPF) involves infiltration of leucocytes, pulmonary injury,
fibrosis and resulting pulmonary dysfunction. Myofibroblasts and transforming growth factor …

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible disease characterized
by an increase in differentiation of fibroblasts to myofibroblasts and excessive accumulation …

Pulmonary fibrosis is a progressive, irreversible, and fatal fibrotic lung disease with a high
mortality and morbidity, and commonly nonresponsive to conventional therapy. Inula …